Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other research analysts have also recently commented on BLPH. ValuEngine cut Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th. Ladenburg Thalmann Financial Services began coverage on Bellerophon Therapeutics in a research note on Monday, April 17th. They issued a “buy” rating and a $4.50 price target for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $3.67.

Shares of Bellerophon Therapeutics (NASDAQ:BLPH) traded down 4.867% during trading on Friday, reaching $1.075. The company’s stock had a trading volume of 272,231 shares. The firm’s 50-day moving average is $1.38 and its 200 day moving average is $1.30. The company’s market cap is $38.17 million. Bellerophon Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.98.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03. On average, equities research analysts predict that Bellerophon Therapeutics will post ($1.12) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/11/bellerophon-therapeutics-inc-blph-lowered-to-hold-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new position in shares of Bellerophon Therapeutics during the first quarter worth approximately $125,000. Renaissance Technologies LLC boosted its position in shares of Bellerophon Therapeutics by 330.8% in the fourth quarter. Renaissance Technologies LLC now owns 239,100 shares of the biotechnology company’s stock worth $124,000 after buying an additional 183,600 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after buying an additional 211,111 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.